(Q35168203)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12839042%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

review article

1 reference

title

Cholesterol absorption inhibitors: defining new options in lipid management (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12839042%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

author name string

W Virgil Brown

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12839042%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

publication date

1 June 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12839042%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12839042%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12839042%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12839042%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

page(s)

259-264

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12839042%20AND%20SRC:MED&resulttype=core&format=json

Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice

5 November 2019

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCLC.4950260604

Lipoprotein lipid response to the National Cholesterol Education Program step II diet by hypercholesterolemic and combined hyperlipidemic women and men.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCLC.4950260604

Mechanism of action of fibrates on lipid and lipoprotein metabolism

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCLC.4950260604

Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease

21 January 2018

1 reference

12 December 2020

Drug treatment of lipid disorders

1 reference

12 December 2020

The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits

1 reference

12 December 2020

Management of hypercholesterolemia

1 reference

12 December 2020

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

1 reference

12 December 2020

Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663

1 reference

12 December 2020

Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics

1 reference

12 December 2020

Pleiotropic effects of statins in atherosclerosis and diabetes

1 reference

12 December 2020

Intestinal absorption of triglyceride and cholesterol. Dietary and pharmacological inhibition to reduce cardiovascular risk

1 reference

12 December 2020

Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia

1 reference

12 December 2020

The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys

1 reference

12 December 2020

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

12 December 2020

Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia

1 reference

12 December 2020

Assessment of hypercholesterolemia control in a managed care organization

1 reference

12 December 2020

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies

1 reference

12 December 2020

Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

1 reference

12 December 2020

Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study

1 reference

12 December 2020

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Dietary cholesterol and the optimal diet for reducing risk of atherosclerosis

1 reference

12 December 2020

Cholesterol-lowering diets. A review of the evidence

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Inadequate treatment with HMG-CoA reductase inhibitors by health care providers

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

1 reference

12 December 2020

Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month

1 reference

12 December 2020

In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461

1 reference

12 December 2020

Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men. The Dietary Alternatives Study.

1 reference

12 December 2020

Rhabdomyolysis after taking atorvastatin with gemfibrozil

1 reference

12 December 2020

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

1 reference

12 December 2020

The Münster Heart Study (PROCAM). Results of follow-up at 8 years.

1 reference

12 December 2020

Lipoprotein metabolism

1 reference

12 December 2020

Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

Postprandial lipemia: emerging evidence for atherogenicity of remnant lipoproteins

1 reference

12 December 2020

Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol

1 reference

12 December 2020

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

12 December 2020

Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention

1 reference

12 December 2020

Postprandial lipaemia and haemostatic factors.

1 reference

12 December 2020

Identifiers

DOI

10.1002/CLC.4950260604

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12839042%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12839042%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

PubMed publication ID

12839042

1 reference